Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.
Jacob Sands, MD
Advertisement
Articles by Jacob Sands, MD
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
Advertisement
Latest Updated Articles
Dato-DXd Shows Favorable Benefit in EGFR-Mutant NSCLCPublished: August 1st 2025 | Updated:
Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC ManagementPublished: August 4th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
2
Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs
3
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
4
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
5
